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Monoacylglycerol lipase (MGL) is a serine hydrolase
involved in the biological deactivation of the endo-
cannabinoid 2-arachidonoyl-sn-glycerol (2-AG). Pre-
vious efforts to design MGL inhibitors have focused
on chemical scaffolds that irreversibly block the
activity of this enzyme. Here, we describe two natu-
rally occurring terpenoids, pristimerin and euphol,
which inhibit MGL activity with high potency (median
effective concentration, IC50 = 93 nM and 315 nM,
respectively) through a reversible mechanism. Muta-
tional and modeling studies suggest that the two
agents occupy a common hydrophobic pocket
located within the putative lid domain of MGL, and
each reversibly interacts with one of two adjacent
cysteine residues (Cys201 and Cys208) flanking such
pocket. This previously unrecognized regulatory
region might offer a molecular target for potent and
reversible inhibitors of MGL.
INTRODUCTION
2-Arachidonoyl-sn-glycerol (2-AG), an endogenous lipid agonist
for cannabinoid (CB) receptors (Sugiura et al., 1995; Mechoulam
et al., 1995; Stella et al., 1997), is thought to modulate excitatory
neurotransmission in the central nervous system by acting as
a synaptic messenger (Katona and Freund, 2008). Electrophysi-
ological, pharmacological, and neuroanatomical evidence sug-
gests that 2-AG is produced in dendritic spines of glutamatergic
synapses and crosses the synaptic cleft in a retrograde direction
to activate presynaptic CB1 receptors and inhibit glutamate
release (Katona and Freund, 2008). CB1-bearing axon terminals
also contain the enzyme monoacylglycerol lipase (MGL) (Gulyas
et al., 2004), a cytosolic serine hydrolase (Karlsson et al., 1997)
that cleaves 2-AG and presumably terminates its transsynaptic
actions (Dinh et al., 2002).
MGL belongs to the ‘‘a/b hydrolase fold’’ family of enzymes,
whoseconserved three-dimensionalstructuresconsistofacentral
b sheet surrounded by a variable number of a helices (Ollis et al.,
1992). The active sites of these proteins are located in turnsChemistry & Biology 16, 1045–between a helices and b sheets and harbor a classic catalytic tri-
ad composed of a serine, a carboxylic acid, and a histidine (Ollis
et al., 1992). Structure-alignment and site-directed mutagenesis
studies have identified residues Ser122, Asp239, and His269 as the
catalytic triad in rodent MGL (Karlsson et al., 1997) Moreover,
mass spectrometry experiments have shown that the substituted
tetrazole AM6701 (5-[(biphenyl-4-yl)methyl]-N,N-dimethyl-2H-
tetrazole-2-carboxamide) inhibits human MGL by covalently
modifying the enzyme’s catalytic serine (Zvonok et al., 2008).
In addition to the Ser-Asp-His triad, 3 cysteine residues
appear to contribute in important ways to the regulation of
MGL function. Computational models position one of these resi-
dues, Cys242, in close proximity of the catalytic triad, whereas
mutational analyses indicate that its replacement with glycine
causes a substantial loss of catalytic activity (King et al., 2009).
Two additional regulatory cysteines, Cys201 and Cys208, are
found on the putative lid domain of MGL, a flexible structure
that is thought to function as an entry gate to the active site of
this and other lipases (Jaeger et al., 1999). Though mutations
affecting Cys201 and Cys208 produce only a moderate decrease
in MGL activity, they markedly reduce the ability of cysteine-
reacting agents to inhibit such activity (King et al., 2009).
The presence of MGL in glutamatergic axon terminals (Gulyas
et al., 2004) suggests that this enzyme might be involved in the
termination of 2-AG-mediated retrograde transmission at excit-
atory synapses. This idea is supported by studies showing that
virally induced MGL overexpression reduces receptor-depen-
dent 2-AG accumulation in primary cultures of rat brain neurons
(Dinh et al., 2002), and that siRNA-mediated MGL silencing
increases 2-AG levels in HeLa cells (Dinh et al., 2004). Pharma-
cological experiments in vivo have provided further support for
a role of MGL in 2-AG deactivation. Microinjections of the carba-
mate-based MGL inhibitor URB602 (biphenyl-3-ylcarbamic
acid cyclohexyl ester) into the periaqueductal gray region of
the midbrain increased 2-AG levels and enhanced stress-
induced analgesia in rats (Hohmann et al., 2005). Moreover,
local or systemic URB602 administration reduced nocifensive
responses elicited in rodents by experimental nerve injury
(Desroches et al., 2008) and by injections of formalin (Guindon
et al., 2007) or carrageenan (Comelli et al., 2007). More recently,
the potent carbamate-based MGL inhibitor JZL-184 (4-(bis-ben-
zo[1,3]dioxol-5-yl-hydroxy-methyl)-piperidine-1-carboxylic acid
4-nitro-phenyl ester) was shown to produce a classical set1052, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1045
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behavior, body temperature, and motor activity—when injected
in mice (Long et al., 2009a). Administration of JZL-184 also
elevates 2-AG levels in peripheral tissues, highlighting the impor-
tant role of MGL in the hydrolysis of 2-AG outside the brain (Long
et al., 2009b), where this endocannabinoid was originally discov-
ered (Mechoulam et al., 1995).
All potent inhibitors of MGL activity reported thus far—
including carbamates (Long et al., 2009a, 2009b; Muccioli
et al., 2008), maleimides (Saario et al., 2005), tetrazoles (Zvonok
et al., 2008), and isothiazolinones (King et al., 2009)—exert their
effects by forming covalent bonds with reactive serine or
cysteine residues. Because there are potential clinical disadvan-
tages to this mode of action, in the present study we screened
a commercial chemical library to identify scaffolds that might
be utilized to design reversible MGL inhibitors. We describe
the discovery of two bioisosteric terpenoids, pristimerin and
euphol, which inhibit MGL with high potency by interacting in
a reversible manner with a novel regulatory region of MGL.
RESULTS AND DISCUSSION
Pristimerin Inhibits MGL
The screening of the chemical library revealed the presence of
multiple active compounds. Because of its high potency, we
selected for further studies the friedelane triterpenoid, pristi-
merin (Table 1) (Dev et al., 1989). Pristimerin inhibited the activity
of purified MGL with a median effective concentration (IC50) of
93 ± 8 nM (mean and standard error of the mean [SEM]; n = 3)
and that of nonpurified MGL (cell lysates of MGL-transfected
HeLa cells) with an IC50 of 398 ± 68 nM (n = 4) (Figure 1A). The
difference in potency observed between these two preparations
might reflect the presence of competing reactions in the crude
HeLa extract and/or inadequate posttranslational modifications
of the E. coli protein.
Other friedelane triterpenoids represented in the library also
inhibited MGL activity, albeit less potently than pristimerin did.
These included celastrol, pristimerol, dihydrocelastrol, and
dihydrocelastryl diacetate (Table 1). The inhibitory potencies of
these compounds appeared to be particularly sensitive to
chemical modifications at the two opposite ends of their rigid
terpenoid scaffold: the esterification of the carboxyl group at
carbon 29, which increased inhibitory activity, and the reduction
of the quinone methide ring, which decreased such activity
(Table 1).
Pristimerin Is a Reversible MGL Inhibitor
The quinone methide group tends to react with cysteine residues
in proteins to form covalent adducts (Bolton et al., 1997).
To determine whether pristimerin might act through a similar
mechanism, we studied the interaction of this compound with
purified MGL using a rapid dilution assay (King et al., 2009; Cope-
land, 2005). Under the conditions of this test, incubation of MGL
with a covalent inhibitor—for example, the serine-reactive agent
methyl arachidonylfluorophosphonate (MAFP)—resulted in the
formation of an enzyme-inhibitor complex that is resistant to dilu-
tion of the assay mixture (Figure 1B) (King et al., 2009). By
contrast, rapid dilution of the MGL-pristimerin mixture resulted
in a virtually complete recovery of catalytic activity, which is
suggestive of a reversible inhibition (Figure 1B). Time-course
experiments showed that addition of pristimerin to purified
MGL produces an almost immediate blockade of MGL activity
(Figure 1C). Additional kinetic studies using nonpurified HeLa
MGL demonstrated that pristimerin decreases the maximal
Table 1. Inhibition of Purified Recombinant MGL by Friedelane-
Based Pentacyclic Triterpenoids
Compound Structure IC50
1 Pristimerin
HO
O
O O 93 ± 8 nM
2 Celastrol
O
HO
O OH 1.6 ± 0.4 mM
3 Pristimerol
HO
HO
O O 4 ± 0.5 mM
4 Dihydrocelastrol
HO
O OH
HO
15 ± 4 mM
5 Dihydrocelastryl
Diacetate
O
O OH
O
O
O
15 ± 3 mM
Results are expressed as mean ± SEM (n = 3–4).1046 Chemistry & Biology 16, 1045–1052, October 30, 2009 ª2009 Elsevier Ltd All rights reserved
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Potent and Reversible MGL Inhibitorscatalytic velocity of this enzyme (Vmax in pmol/min/mg; vehicle,
200 ± 20, n = 11; 100 nM, 174 ± 7, n = 3; 300 nM, 104 ± 7, n =
4; 500 nM, 51 ± 18, n = 3; p < 0.005) without influencing its
Michaelis-Menten constant (Km in mM; vehicle, 28 ± 4; 100 nM,
27 ± 1; 300 nM, 24 ± 5; 500 nM, 14 ± 2; p > 0.3) (Figure 1D).
Together, the results indicate that pristimerin inhibits MGL through
a mechanism that is rapid, reversible, and noncompetitive.
Euphol Is a Bioisoster of Pristimerin
To further evaluate the role of the quinone methide group, we
examined whether bioisosters of pristimerin that lack this moiety
might also inhibit MGL activity. A computational analysis of
structures represented in the chemical library revealed that the
triterpene alcohol, euphol (Dev et al., 1989), takes a minimum
energy conformation that is superimposable to the rigid scaffold
of pristimerin, allowing the hydroxyl groups of the two molecules
to overlap (Figure 2A). Enzyme assays showed that euphol
inhibits purified MGL with an IC50 of 315 ± 1 nM (n = 3) and non-
purified HeLa MGL with an IC50 of 882 ± 78 nM (n = 3) (Figure 2B).
Moreover, rapid dilution and kinetic experiments demonstrated
that euphol blocks MGL activity through a reversible and non-
competitive mechanism, which is apparently identical to that of
pristimerin (Figures 2C and 2D).
Interactions with Regulatory Cysteines: Modeling
Studies
The structural and mechanistic similarities between pristimerin
and euphol prompted us to examine whether the two
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Figure 1. Pristimerin Inhibits MGL
(A) Concentration-dependent inhibition of purified
MGL (squares, n = 3) and HeLa MGL (circles, n = 4)
by pristimerin.
(B) Rapid dilution assays of HeLa-MGL in the pres-
ence of vehicle (squares, DMSO, final concentra-
tion 2%), pristimerin (triangles), or MAFP (circles).
We measured the amount of reaction product
(pmol/mg protein) generated over a 60 min period
following a 20 min preincubation with inhibitor or
vehicle (n = 3).
(C) Time course of MGL inhibition by pristimerin
(300 nM, n = 3).
(D) Michaelis-Menten analysis of the MGL reaction
(measured as pmol/min/mg protein) in the pres-
ence of vehicle (squares, DMSO, 1%) (n = 4) or
pristimerin (100 nM, 300 nM, or 500 nM; n = 3–4).
Enzyme activity is reported as percent of vehicle
controls (DMSO, 1%). Results are expressed
as mean ± SEM, with each assay performed in
duplicate.
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Figure 2. Euphol Is a Bioisoster of MGL
(A) Chemical structure of euphol (top) and three-
dimensional superposition of euphol (gold) and
pristimerin (green). Oxygens, red; hydrogens,
blue.
(B) Concentration-dependent inhibition of purified
MGL (squares) and HeLa MGL (circles) by euphol.
Enzyme activity is reported as percent of vehicle
controls (DMSO, 1%). Results are expressed as
mean ± SEM (n = 3).
(C) Rapid dilution assays of HeLa-MGL in the pres-
ence of vehicle (squares, DMSO, final concentra-
tion 2%), euphol (triangles), or MAFP (circles).
We measured the amount of reaction product
(pmol/mg protein) generated over a 60 min period
following a 20 min preincubation with inhibitor or
vehicle. Results are expressed as mean ± SEM
(n = 3).
(D) Michaelis-Menten analysis of the MGL reaction
in the presence of vehicle (squares, DMSO, 1%)
(n = 4) or euphol (900 nM). Results are expressed
as mean ± SEM (n = 3).Chemistry & Biology 16, 1045–1052, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1047
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Potent and Reversible MGL Inhibitorscompounds might interact with a common binding pocket in
MGL. As a first test of this hypothesis, we utilized an induced-
fit docking (IFD) protocol (Sherman et al., 2006) to compare the
binding poses adopted by pristimerin and euphol in a refined
computational model of MGL (King et al., 2009; Saario et al.,
2005). Figure 3A illustrates a docking solution for pristimerin
in which the lipophilic portion of the molecule lies on a
pocket located within the lid domain of MGL and its 3-hydroxyl
group faces the regulatory cysteines, Cys201 and Cys208 (King
et al., 2009). This solution was further probed using molecular
dynamics (MD) simulations. Starting from the orientation
depicted in Figure 3A, pristimerin was found to oscillate around
its initial conformation with a ligand atom root-mean-square
distance (RMSD) of 0.36 ± 0.08 A˚. Average distances between
the polar hydrogen of the 3-hydroxyl group of pristimerin and
the sulfur atoms of Cys208 and Cys201 were 2.90 ± 0.25 A˚ and
3.22 ± 0.27 A˚, respectively. This suggests that the binding of
pristimerin to MGL might be strengthened by formation of a polar
interaction with a regulatory cysteine, possibly Cys208.
A subsequent set of IFD analyses showed that euphol can
be readily superposed on pristimerin so that its 3-hydroxyl
group faces Cys208 and Cys201 (Figure 3B,C). Notably, however,
the interaction of euphol with Cys208 was lost in the early
phase of the simulation (average hydrogen-sulfur distance =
4.00 ± 0.31 A˚), whereas the interaction with Cys201 turned out
to be significantly more stable (average hydrogen-sulfur dis-
tance, 3.13 ± 0.39 A˚). During MD simulations, euphol had a higher
RMSD compared with pristimerin (0.96 ± 0.09 A˚), mainly owing
to a change in the conformation of its tail at C17. A plausible
interpretation of these results is that pristimerin and euphol
occupy a common hydrophobic pocket within the lid domain
of MGL, and each inhibitor engages through polar interactions
1 of 2 adjacent cysteine residues, Cys201 and Cys208, which
flank this pocket. The limited overlap of the region occupied
by pristimerin and euphol with the presumptive active site
of MGL (Figure 3D) is consistent with the noncompetitive
kinetic behavior displayed by these inhibitors. However, there
are other possible explanations for such behavior, including
Figure 3. Interaction of Pristimerin and Euphol with Regulatory Cysteines
(A and B) Predicted binding modes of pristimerin (A) and euphol (B) to the model of rat MGL, showing their possible interactions with Cys208 and Cys201. The
docking pose adopted by pristimerin predicts an additional interaction with a neighboring glutamine residue (Gln212).
(C) Superposition of the two models.
(D) Docking pose for 2-AG in the presumptive active site of MGL [10] along with the putative region of overlap with pristimerin and euphol. MGL carbons black;
pristimerin, green; euphol, gold; 2-AG, gray; oxygens, red; hydrogens, blue; sulfurs, yellow; nitrogens, dark blue; lid domain, magenta; a/b core, white.1048 Chemistry & Biology 16, 1045–1052, October 30, 2009 ª2009 Elsevier Ltd All rights reserved
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Figure 4. Effect of Cysteine Mutations on
MGL Inhibition by Pristimerin and Euphol
Effects of mutating Cys201 or Cys208 on MGL inhi-
bition by pristimerin (A) and euphol (B). Concentra-
tion-response curves for the inhibition of wild-type
MGL (wt, squares) and MGL mutants containing
cysteine-to-glycine mutations at either Cys201
(C201G, triangles) or Cys208 (C208G, circles).
Enzyme activity is reported as percent of vehicle
controls (DMSO, 1%). Results are expressed as
mean ± SEM (n = 4-9). p < 0.0001, ANOVA, fol-
lowed by Dunnett’s test.stabilization of a conformation of MGL that is inaccessible to the
substrate.
Interaction with Regulatory Cysteines: Mutational
Analyses
A prediction of our theoretical model is that mutations affecting
either Cys208 or Cys201 should differentially affect the inhibitory
potencies of pristimerin and euphol. To test this possibility, we
mutated the two cysteines into glycines, expressed the mutants
in HeLa cells, and determined the inhibitory effects of pristimerin
and euphol on MGL activity in cell extracts. The replacement
of Cys208 caused a marked rightward shift in the concentra-
tion-response curve for pristimerin (Figure 4A) (IC50; wt = 350 ±
37 nM; C208G = 1182 ± 174 nM; n = 6; p < 0.0001), whereas it
had no effect on euphol (Figure 4B). Conversely, a mutation
affecting Cys201 significantly reduced the inhibitory potency of
euphol (Figure 4B) (IC50; wt = 513 ± 9 nM; C201G = 2601 ±
200 nM; n = 4; p < 0.0001) without affecting the potency of pris-
timerin (Figure 4A). Mutating a cysteine residue that is distant
from both active site and lid domain, Cys32, did not influence
the activity of either agent (data not shown). The results support
the validity of the computational model illustrated in Figure 3D,
suggesting that reversible interactions of pristimerin and euphol
with Cys208 and Cys201, respectively, contribute to the inhibitory
potencies of these two agents.
Effects of Pristimerin in Intact Rat Brain Neurons
We next asked whether reversible inhibition of MGL activity,
such as that produced by pristimerin and euphol, might effec-
tively protect 2-AG from degradation in intact brain neurons,
which contain relatively high concentrations of 2-AG and other
monoacylglycerols that are substrates for MGL. Incubation
of primary cultures of rat cortical neurons with the cysteine-
reactive MGL inhibitor, N-arachidonylmaleimide (1 mM, 25 min)
(Saario et al., 2005), increased the levels of 2-AG and palmitoy-
lethanolamide (PEA), a noncannabinoid fatty-acid ethanolamide
that is primarily hydrolyzed, in neurons, by fatty-acid amide
hydrolase (FAAH) (Figure 5) (De´sarnaud et al., 1995; Cravatt
et al., 1996). Under the same experimental conditions, incuba-
tion with pristimerin (1 mM, 30 min) caused an elevation in cellular
2-AG concentrations (1.6 ± 0.1 fold change, n = 3), which
was not accompanied by any significant changes in PEA (Fig-
ure 5). As expected from its weaker inhibitory potency, euphol
(10 mM, 30 min) caused a small, nonsignificant change in the
levels of 2-AG (1.2 ± 0.2 fold change, n = 3) and PEA (data not
shown).Chemistry & Biology 16, 1045–1The results described above suggest that pristimerin preferen-
tially inhibits 2-AG hydrolysis in intact brain neurons. Consistent
with this conclusion, a survey of endocannabinoid-metabolizing
enzymes showed that pristimerin had no significant effect,
in vitro, on the activities of rat brain diacylglycerol lipase (a serine
hydrolase responsible for the production of 2-AG) (Bisogno et al.,
2003), rat brain FAAH, and rat recombinant N-acylethanolamide
acid amidase (a cysteine amidase involved in the degradation of
PEA and other fatty-acid ethanolamides) (see Table S1 available
online) (Cravatt et al., 1996; Ueda et al., 2001). Though pristi-
merin did not affect the activity of the 2-AG hydrolase
ABHD12, it was potent at inhibiting the activity of another
2-AG-hydrolyzing enzyme, ABHD6 (IC50 = 98 ± 8 nM, n = 3)
(Blankman et al., 2007). ABHD6 displays a closer sequence
homology with MGL than ABHD12 does (in sequence similarity;
MGL and ABHD6, 33%; ABHD6 and ABHD12, 26.3%). Euphol
produced a similar, albeit weaker inhibitory effect on ABHD6
(IC50 = 9 ± 1 mM, n = 6).
SIGNIFICANCE
MGL is localized to axon terminals throughout the brain and
is thought to participate in the physiological elimination of
***
***
*ns
Figure 5. Pristimerin Protects 2-AG from Degradation in Neurons
Effects of pristimerin (1 mM), NAM (1 mM), or vehicle (0.1% DMSO in DMEM) in
primary cultures of rat cortical neurons. Levels of 2-AG and PEA are reported
as fold change over vehicle-treated neurons. Results are expressed as mean ±
SEM (n = 5). ****p < 0.0001, ***p < 0.001, *p < 0.05, ns = not significant,
unpaired Student’s t test.052, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1049
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macological blockade of MGL activity exerts multiple effects
in live animals, including profound antinociception in models
of acute and chronic pain. The irreversible mechanism of
action of all potent MGL inhibitors described so far presents,
however, possible clinical issues (e.g., the formation of
antigenic adducts with plasma proteins) that might eventu-
ally hinder the therapeutic use of these agents. To overcome
these potential limitations, in the present study we screened
a commercial chemical library to identify structural motifs
that might be utilized as a starting point for the design of
reversible MGL inhibitors. Our screen led to the discovery
of two bioisosteric terpenes, pristimerin and euphol,
which inhibit MGL activity through a reversible mechanism
and with high potency in vitro. Investigations into the
inhibitory properties of these agents—utilizing a combina-
tion of biochemical, molecular modeling, and mutagenesis
approaches—suggest that they occupy a common hydro-
phobic pocket located within the a-helical lid domain of
MGL, and each interacts reversibly with either of 2 neigh-
boring cysteines present at the border of such pocket:
Cys201 and Cys208. Notably, prior studies had already impli-
cated these residues in the covalent inhibition of MGL by iso-
thiazolinone derivatives (King et al., 2009). The identification
of this regulatory region of MGL provides a novel molecular
target for the generation of potent and reversible inhibitors.
EXPERIMENTAL PROCEDURES
Chemicals
Compounds 1-6 were part of the Spectrum Collection, purchased from Micro-
Source Discovery Systems Inc. (Gaylordsville, CT). MAFP and NAM were
obtained from Cayman Chemical (Ann Arbor, MI), 2-oleoyl-sn-glycerol
(2-OG) from Indofine Chemical (Hillsborough, NJ), and 2-[2H8]-AG from
Cayman Chemical; [2H4]-PEA was synthesized as described previously
(Fegley et al., 2005).
Screening for MGL Inhibitors
The Spectrum Collection (MicroSource Discovery Systems, retrieved May 20,
2009, from http://www.msdiscovery.com/home.html) is composed of 2000
compounds, supplied in a 10 mM dimethyl sulfoxide (DMSO) solution. We
pooled groups of 10 compounds and performed a primary screen at a concen-
tration of 1 mM. Individual compounds from positive groups (R50% MGL
inhibition) were subjected to a secondary screen at 10 mM. Full concentra-
tion-inhibition curves were generated using new lots of dry compounds.
Enzyme Assays
Purified recombinant rat MGL was prepared and enzyme activity was assayed
as described previously (King et al., 2007). Full-length rat ABHD6 or ABHD12
was subcloned into a pEF-V5/His vector by TOPO cloning (Invitrogen, Carls-
bad, CA) and verified by DNA sequencing. HeLa cells were transiently trans-
fected with pEF6 vector, ABHD6-V5-pEF6 or ABHD12-V5-pEF6 using Super-
fect reagent (QIAGEN, Valencia, CA). Forty-eight hours after transfection, cells
were harvested and the homogenates were prepared in 50 mM Tris-Cl (pH 8.0)
containing 0.32 M sucrose. ABHD activity was measured using a modified
MGL assay procedure (pH 7.5, 3 mg protein per reaction, 30 min at 37C)
(King et al., 2007). Samples were extracted (King et al., 2007) and analyzed
by liquid chromatography/mass spectrometry (LC/MS) (see below). 2-AG-
hydrolase activity (in pmol/min/mg protein) in mock-transfected HeLa cells
was 1.4 ± 0.05, in pEF6-transfected (vector only) was 1.3 ± 0.01, and in
ABHD6-transfected cells was 6.9 ± 0.2 (n = 3). FAAH and DGL activities
were measured in rat brain homogenates as described elsewhere (Stella
et al., 1997). Recombinant NAAA protein was prepared from HEK293 cells
stably transfected with pCMV-Flag-rNAAA using SuperFect reagent (QIAGEN)1050 Chemistry & Biology 16, 1045–1052, October 30, 2009 ª2009and screened with G418 (0.3 mg/ml). Cells were harvested and sonicated in
20 mM Tris-HCl (pH 7.5) with 0.32 M sucrose, centrifuged at 800 3 g for
15 min at 4C, and supernatant was centrifuged at 12,000 3 g for 30 min
at 4C. The pellet was suspended in phosphate-buffered saline (PBS) and
subjected to 2 freeze-thaw cycles at 80C. The suspension was centrifuged
at 105,0003 g for 1 hr at 4C, and the supernatant containing rNAAA was kept
at 80C until use. NAAA activity was measured by combining substrate
(50 mM heptadecenoylethanolamide) with protein (10 mg) in assay buffer
(50 mM sodium hydrogen phosphate buffer [pH 5.0], 0.1% Triton X-100,
3 mM DTT) in a final volume of 0.2 ml for 30 min at 37C. Reactions were
stopped by addition of 0.2 ml cold methanol containing 1 nmol heptadecanoic
acid (NuChek Prep, Elysian, MN). For MGL, ABHD, and NAAA assays, samples
were analyzed by LC/MS on an XDB Eclipse C18 column (2.1 3 30 mm i.d.,
1.8 mm,) at 0.6 ml/min for 0.6 min with a solvent mixture of 95% methanol
and 5% water, both containing 0.25% acetic acid and 5 mM ammonium
acetate. The column temperature was 50C. Samples were analyzed by
electrospray ionization in the negative mode. Capillary voltage was 4 kV, frag-
mentor voltage was 100 V, nebulizer pressure was 60 psi. N2 was used as
drying gas at a flow rate of 13 l/min and a temperature of 350C. We monitored
the appropriate enzyme activity product (MGL and ABHD, m/z = 281, NAAA,
m/z = 267) in the selected ion monitoring mode using heptadecanoic acid as
standard (m/z = 269).
Site-Directed Mutagenesis
Generation of cysteine-to-glycine point mutants by site-directed mutagenesis
and subsequent transfections in HeLa cells were performed as previously
described (King et al., 2009).
Neuron Cultures
Primary cortical neuron cultures were prepared from embryonic day 18-20
Wistar rats (Stella and Piomelli, 2001). Cultures were maintained for 10 days
at 37C with 5% CO2 before treatment with pristimerin (1 mM), euphol
(10 mM), NAM (1 mM), or vehicle (0.1% DMSO in Dulbecco’s modified Eagle
medium [DMEM]) for 30 min at 37C. Reactions were stopped by washing
with ice-cold PBS and cells were harvested in 2 ml 50% methanol. Lysates
were vortexed for 10 s, protein concentrations were measured by bicincho-
ninic acid protein assay (Pierce, Rockford, IL), and samples were extracted
in 4 ml ice-cold methanol/chloroform/water (1:2:1, vol:vol:vol) containing
0.5 nmol 2-[2H8]-AG, and 10 pmol each of [
2H4]-PEA, added as internal stan-
dard. Organic phases were recovered, evaporated under N2, reconstituted
in 50 ml chloroform/methanol (1:3, vol:vol), and analyzed by LC/MS as
described previously (Astarita and Piomelli, 2009).
Computational Modeling
Docking studies were carried out using the IFD approach (King et al., 2009)
based on Prime 1.7 (Schro¨dinger, LLC, New York, NY) and Glide 5.0 (Schro¨-
dinger, LLC, New York, NY) molecular modeling software. Coordinates of rat
MGL were taken from a previously published model of the enzyme in complex
with 2-AG (King et al., 2009). Inhibitors were built using Maestro 8.5 (Schro¨-
dinger, LLC) and their geometries were optimized to an energy gradient of
0.01 kcal/(mol$A˚)with the OPLS2005 force field (Jorgensen et al., 1996). In
turns, the inhibitors were placed in an arbitrary position within a region
centered on residues Cys201, Cys208, or Cys242 of MGL using enclosing and
bounding boxes of 20 A˚ and 10 A˚ on each side, respectively. For the IFD
protocol, an initial softened-potential docking of the ligand to the rigid receptor
was performed, with van der Waals radii scaling of 0.5 for both MGL and ligand
nonpolar atoms. Sampling of the protein conformation for each of the top 20
ligand poses (ranked by Glide) was performed using Prime. In this phase, resi-
dues within 5 A˚ of the ligand pose were refined by side-chain conformational
search followed by full minimization of the residues and the ligand. Complexes
within 30.0 kcal/mol of minimum energy structure were taken forward for
redocking. The related ligand was redocked into each low-energy, induced-
fit structure with default Glide settings (van der Waals radii scaling of 1.0 for
MGL and 0.8 for the ligand). Each complex was then ranked according to
the IFD score.
Molecular dynamics simulations of the IFD complexes were performed
using OPLS2005 force field in combination with the surface generalized
Born (SGB) continuum model for solvent (water) representation. SHAKEElsevier Ltd All rights reserved
Chemistry & Biology
Potent and Reversible MGL Inhibitorsfunction was used and a time step of 2 fs was applied for 2 ns simulation at 300
K, after an equilibration phase of 200 ps at the same temperature. Backbone
atoms were frozen during the simulations to preserve MGL tertiary structure.
Interactions between the 3-hydroxyl group of the inhibitors and cysteine
sulfur atoms were monitored during the simulations. Distances are reported
as average values over 200 snapshots extracted from MD trajectory.
Pristimerin and euphol were aligned by a rigid fit procedure superposing the
carbon atoms of ring A, B, and C. The minimum energy conformation of euphol
giving the best fit in terms of RMSD was selected for modeling purpose.
SUPPLEMENTAL DATA
Supplemental data include a table and can be found with the article online at
http://www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00322-6.
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